Short answer
Baxter International (BAX) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 provides operational sales growth for 2025 and organic sales growth for Q1 2026.
Baxter International 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 provides operational sales growth for 2025 and organic sales growth for Q1 2026
- Growth metrics exclude Kidney Care MSA effects and use constant-currency comparisons
- Operational growth additionally excludes IV solutions exit in China within the MPT segment
- Non-GAAP metrics improve comparability but require reconciliation with U.S. GAAP sales growth
Item EX-99.1 · Exhibit EX-99.1
- Revised segment basis shows FY2025 sales $11.244B, up 6% reported but only 3% operationally after Kidney Care MSA effects
- Advanced Surgery strongest FY2025 segment, sales $1.198B and 8% operational growth
- FY2025 operating income fell to $(308)M from $14M, despite reportable segment operating income rising to $2.246B
- FY2025 included $485M goodwill impairments and $290M indefinite-lived asset impairments, materially depressing reported profitability
- Q1 2026 sales $2.701B, up 3% reported but down 1% organically, with Medical Products & Therapies organic sales down 1%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Baxter International 8-K filings
Get the next BAX 8-K as it lands
Follow BAX for push alerts, or ask the research agent what this filing means.